| Schedule of Segment Profit or Loss, Including Significant Segment Expenses |
The table below provides a summary of the segment profit or loss, including significant segment expenses:
|
|
|
|
|
|
|
|
|
Year Ended
December 31, |
|
|
2024 |
|
|
2023 |
|
Revenues |
|
|
|
|
|
License revenue - related party |
$ |
5,909 |
|
|
$ |
2,826 |
|
License revenue |
|
326 |
|
|
|
— |
|
Total revenues |
|
6,235 |
|
|
|
2,826 |
|
Research and development expenses: |
|
|
|
|
|
DNTH103 program-related expenses: |
|
|
|
|
|
Clinical operation activities |
|
25,764 |
|
|
|
4,931 |
|
CMC activities |
|
19,494 |
|
|
|
5,969 |
|
Preclinical study costs |
|
8,537 |
|
|
|
7,024 |
|
Other costs |
|
600 |
|
|
|
100 |
|
Total DNTH103 program-related expenses |
|
54,395 |
|
|
|
18,024 |
|
Personnel and related costs |
|
16,638 |
|
|
|
9,515 |
|
Share-based compensation |
|
5,576 |
|
|
|
897 |
|
Discovery expenses |
|
2,117 |
|
|
|
1,426 |
|
Other costs |
|
4,379 |
|
|
|
2,979 |
|
Total research and development expenses |
|
83,105 |
|
|
|
32,841 |
|
General and administrative expenses: |
|
|
|
|
|
Personnel and related costs |
|
8,249 |
|
|
|
9,600 |
|
Share-based compensation |
|
7,318 |
|
|
|
2,003 |
|
Other costs |
|
9,427 |
|
|
|
6,556 |
|
Total general and administrative expenses |
|
24,994 |
|
|
|
18,159 |
|
Other income, net |
|
16,895 |
|
|
|
4,619 |
|
Net loss |
$ |
(84,969 |
) |
|
$ |
(43,555 |
) |
|